Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences

Andrea King, Harriet de Wit, Roslynn C. Riley, Dingcai Cao, Raymond Niaura, Dorothy Hatsukami

Research output: Contribution to journalArticle

Abstract

This double-blinded, placebo-controlled trial evaluated the efficacy of naltrexone as an adjunct to standard smoking cessation treatment. Participants (N=110) were adult male and female nicotine-dependent smokers who expressed interest in quitting smoking. All subjects received six sessions of behavioral counseling (1 hr/session for 6 weeks), and 1 month of the nicotine patch (21 mg for the first 2 weeks, 14 mg the third week, 7 mg the fourth week). Subjects were randomly assigned to the naltrexone or placebo group. The naltrexone group started at 25 mg daily for 3 days prior to the quit date, and increased to 50 mg/day on the quit date and following 8 weeks. At the end of medication treatment, the naltrexone group had better quit rates versus the placebo group (48% quit on naltrexone vs. 41% on placebo), but this difference was not statistically significant. However, men and women differed on several measures: in the placebo group, women had significantly lower quit rates than men (39% vs. 67%, p<.05), but in the naltrexone group, women had quit rates comparable with those of men (58% vs. 62%, p=ns). Further examination revealed that naltrexone significantly reduced men's and women's cessation-related weight gain and selectively reduced women's urge to smoke to relieve negative affect and withdrawal. The results suggest continued examination of naltrexone as an adjunct in smoking cessation, particularly in female smokers, who have historically shown worse outcomes with traditional treatment methods.

Original languageEnglish (US)
Pages (from-to)671-682
Number of pages12
JournalNicotine and Tobacco Research
Volume8
Issue number5
DOIs
StatePublished - Oct 2006

Fingerprint

Naltrexone
Smoking Cessation
Sex Characteristics
Placebos
Tobacco Use Cessation Products
Withholding Treatment
Nicotine
Smoke
Weight Gain
Counseling
Smoking
Therapeutics

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Efficacy of naltrexone in smoking cessation : A preliminary study and an examination of sex differences. / King, Andrea; de Wit, Harriet; Riley, Roslynn C.; Cao, Dingcai; Niaura, Raymond; Hatsukami, Dorothy.

In: Nicotine and Tobacco Research, Vol. 8, No. 5, 10.2006, p. 671-682.

Research output: Contribution to journalArticle

King, Andrea ; de Wit, Harriet ; Riley, Roslynn C. ; Cao, Dingcai ; Niaura, Raymond ; Hatsukami, Dorothy. / Efficacy of naltrexone in smoking cessation : A preliminary study and an examination of sex differences. In: Nicotine and Tobacco Research. 2006 ; Vol. 8, No. 5. pp. 671-682.
@article{3ae306ef51554ac8b4a49d7f101bd167,
title = "Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences",
abstract = "This double-blinded, placebo-controlled trial evaluated the efficacy of naltrexone as an adjunct to standard smoking cessation treatment. Participants (N=110) were adult male and female nicotine-dependent smokers who expressed interest in quitting smoking. All subjects received six sessions of behavioral counseling (1 hr/session for 6 weeks), and 1 month of the nicotine patch (21 mg for the first 2 weeks, 14 mg the third week, 7 mg the fourth week). Subjects were randomly assigned to the naltrexone or placebo group. The naltrexone group started at 25 mg daily for 3 days prior to the quit date, and increased to 50 mg/day on the quit date and following 8 weeks. At the end of medication treatment, the naltrexone group had better quit rates versus the placebo group (48{\%} quit on naltrexone vs. 41{\%} on placebo), but this difference was not statistically significant. However, men and women differed on several measures: in the placebo group, women had significantly lower quit rates than men (39{\%} vs. 67{\%}, p<.05), but in the naltrexone group, women had quit rates comparable with those of men (58{\%} vs. 62{\%}, p=ns). Further examination revealed that naltrexone significantly reduced men's and women's cessation-related weight gain and selectively reduced women's urge to smoke to relieve negative affect and withdrawal. The results suggest continued examination of naltrexone as an adjunct in smoking cessation, particularly in female smokers, who have historically shown worse outcomes with traditional treatment methods.",
author = "Andrea King and {de Wit}, Harriet and Riley, {Roslynn C.} and Dingcai Cao and Raymond Niaura and Dorothy Hatsukami",
year = "2006",
month = "10",
doi = "10.1080/14622200600789767",
language = "English (US)",
volume = "8",
pages = "671--682",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Efficacy of naltrexone in smoking cessation

T2 - A preliminary study and an examination of sex differences

AU - King, Andrea

AU - de Wit, Harriet

AU - Riley, Roslynn C.

AU - Cao, Dingcai

AU - Niaura, Raymond

AU - Hatsukami, Dorothy

PY - 2006/10

Y1 - 2006/10

N2 - This double-blinded, placebo-controlled trial evaluated the efficacy of naltrexone as an adjunct to standard smoking cessation treatment. Participants (N=110) were adult male and female nicotine-dependent smokers who expressed interest in quitting smoking. All subjects received six sessions of behavioral counseling (1 hr/session for 6 weeks), and 1 month of the nicotine patch (21 mg for the first 2 weeks, 14 mg the third week, 7 mg the fourth week). Subjects were randomly assigned to the naltrexone or placebo group. The naltrexone group started at 25 mg daily for 3 days prior to the quit date, and increased to 50 mg/day on the quit date and following 8 weeks. At the end of medication treatment, the naltrexone group had better quit rates versus the placebo group (48% quit on naltrexone vs. 41% on placebo), but this difference was not statistically significant. However, men and women differed on several measures: in the placebo group, women had significantly lower quit rates than men (39% vs. 67%, p<.05), but in the naltrexone group, women had quit rates comparable with those of men (58% vs. 62%, p=ns). Further examination revealed that naltrexone significantly reduced men's and women's cessation-related weight gain and selectively reduced women's urge to smoke to relieve negative affect and withdrawal. The results suggest continued examination of naltrexone as an adjunct in smoking cessation, particularly in female smokers, who have historically shown worse outcomes with traditional treatment methods.

AB - This double-blinded, placebo-controlled trial evaluated the efficacy of naltrexone as an adjunct to standard smoking cessation treatment. Participants (N=110) were adult male and female nicotine-dependent smokers who expressed interest in quitting smoking. All subjects received six sessions of behavioral counseling (1 hr/session for 6 weeks), and 1 month of the nicotine patch (21 mg for the first 2 weeks, 14 mg the third week, 7 mg the fourth week). Subjects were randomly assigned to the naltrexone or placebo group. The naltrexone group started at 25 mg daily for 3 days prior to the quit date, and increased to 50 mg/day on the quit date and following 8 weeks. At the end of medication treatment, the naltrexone group had better quit rates versus the placebo group (48% quit on naltrexone vs. 41% on placebo), but this difference was not statistically significant. However, men and women differed on several measures: in the placebo group, women had significantly lower quit rates than men (39% vs. 67%, p<.05), but in the naltrexone group, women had quit rates comparable with those of men (58% vs. 62%, p=ns). Further examination revealed that naltrexone significantly reduced men's and women's cessation-related weight gain and selectively reduced women's urge to smoke to relieve negative affect and withdrawal. The results suggest continued examination of naltrexone as an adjunct in smoking cessation, particularly in female smokers, who have historically shown worse outcomes with traditional treatment methods.

UR - http://www.scopus.com/inward/record.url?scp=33749262497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749262497&partnerID=8YFLogxK

U2 - 10.1080/14622200600789767

DO - 10.1080/14622200600789767

M3 - Article

VL - 8

SP - 671

EP - 682

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 5

ER -